Infection & Immunity

It is estimated that infectious diseases cause a third of all human deaths worldwide. Traditionally, infection and immunity research focuses on understanding pathogens and investigating how they interact with the host immune defenses and why immune regulation sometimes fails, leading to autoimmune diseases. However, the current scope of infection and immunity research is more extensive. This multidisciplinary field spans not only innate and adaptive immunity, autoimmune disorders, infectious diseases, and antimicrobial resistance (AMR), but also non-infectious diseases like cancer. Exploring immune system development and its role in fighting both infections and cancer are crucial to generate new vaccines and develop cancer therapies.

Through the integration of cellular biology, molecular immunology, and clinical insights, researchers seek to identify novel therapeutic targets and design more effective vaccines. Recent advances have significantly deepened the understanding of host–pathogen interactions and immune responses. For instance, meta-analyses of passive antibody treatments for COVID-19 demonstrate that higher neutralizing titers and early administration determine efficacy against emerging variants. Concurrently, strategies combating AMR increasingly emphasize antibiotic stewardship alongside the development of novel agents targeting bacterial biofilm formation and efflux pump mechanisms to overcome resistant pathogens. Progress in Toll-like receptor (TLR) research has identified distinct ligands and adaptor molecules that precisely modulate downstream cytokine profiles, thereby enhancing the design of next-generation vaccine adjuvants and immunotherapies. Furthermore, iPSC-based models derived from patient cells enable detailed investigation of genetic risk factors and provide robust platforms for high-throughput screening of candidate drugs, accelerating the development of personalized therapeutic therapies.

The successful translation of such discoveries fundamentally relies on access to reliable, physiologically relevant cellular tools. AcceGen offers a comprehensive range of products catering to diverse infection and immunity research needs. Primary cells, including T cells, PBMCs, macrophages, and dendritic cells, maintain native immune functions, enabling host–pathogen assays and immunotherapy development. Validated tumor cell lines serve as key models for studying viral tropism and tumor immunology. High-quality immortalized cell lines offer consistent and scalable platforms for high-throughput screening of antiviral or immunomodulatory agents. Additionally, acknowledging the importance of specialized immune modeling, stem cells and iPSC-derived immune cells enable investigation of genetic susceptibility and personalized immune responses.

By combining cutting-edge cellular models with robust immunological insights, AcceGen empowers researchers to expedite vaccine development, decipher resistance mechanisms, and advance next-generation immunotherapies. As infectious threats and AMR continue to evolve, comprehensive cellular toolkits from AcceGen remain essential for translating benchside discoveries into life-saving medical interventions.